Anzeige
Anzeige

Archive

New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: https://doi.org/10.1160/TH10-07-0491
Issue: 2010: 104/6 (Dec) pp. 1083-1289
Pages: 1099-1105

New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

D. A. Garcia (1), R. D. Lopes (2), E. M. Hylek (3)

(1) Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA; (2) Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA; (3) Department of Medicine, Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

Keywords

Clinical trials, thrombosis, heart, oral anticoagulants, stroke prevention

Summary

Atrial fibrillation is a common condition that increases the risk of stroke in many patients. Although warfarin has been shown to reduce the risk of stroke, many patients who might benefit from anticoagulation do not receive this therapy. Fear of bleeding is the most often cited reason. Several new anticoagulant medications are being studied to determine their efficacy and safety relative to warfarin. Unlike earlier trials that established the superiority of warfarin over placebo, recent trials in atrial fibrillation have enrolled a disproportionate number of patients already taking warfarin. This review suggests that the risk of both haemorrhage and stroke are highest when atrial fibrillation is newly diagnosed and during the initiation of anticoagulant medication. Randomised controlled trials designed to evaluate the safety and efficacy of new anti-thrombotic agents should include substantial numbers of patients without prior exposure to anticoagulation since these individuals are at the highest risk for bleeding and thromboembolism.

You may also be interested in...

1.

Online Supplementary Material

R. Nieuwlaat (1, 2), L. M. Hubers (1), A. C. Spyropoulos (3), J. W. Eikelboom (1, 4), B. J. Connolly (1), H. G. C. Van Spall (1, 4), K. M. Schulze (1), S. M. Cuddy (1), A. C. Stehouwer (1), S. Schulman (4), S. J. Connolly (1, 4)

Thromb Haemost 2012 108 6: 1228-1235

https://doi.org/10.1160/TH12-06-0433

2.
Mohammad Urooj Zafar 1, David A. Vorchheimer 1, Juan Gaztanaga 1, Mauricio Velez 1, Daniel Yadegar 1, Pedro R. Moreno 1, Satoshi Kunitada 2, Juan Pagan 2, Valentin Fuster 1, Juan J. Badimon1

Thromb Haemost 2007 98 4: 883-888

https://doi.org/10.1160/TH07-04-0312

3.

Theme Issue Article for Theme Issue "New oral anticoagulants"

N. C. Chan (1, 3), J. S. Paikin (2), J. Hirsh (2, 3), M. N. Lauw (1, 2, 4), J. W. Eikelboom (1, 2, 3), J. S. Ginsberg (2, 3)

Thromb Haemost 2014 111 5: 798-807

https://doi.org/10.1160/TH13-11-0918